Ulrik Niels Lassen

Ulrik Niels Lassen

Clinical Professor

Member of:

  • Clinical Oncology


Publication year:
All
1 - 18 out of 18Page size: 25
  1. 2019
  2. Published

    An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer

    Morgensztern, D., Karaseva, N., Felip, E., Delgado, I., Burdaeva, O., Dómine, M., Lara, P., Paik, P. K., Lassen, Ulrik Niels, Orlov, S., Trigo, J., Shomova, M., Baker-Neblett, K., Vasquez, J., Wang, X., Yan, L., Mitrica, I., DeYoung, M. P. & Garrido, P., Oct 2019, In: Lung Cancer. 136, p. 74-79

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Socioeconomic Differences in Referral to Phase I Cancer Clinical Trials: A Danish Matched Cancer Case-Control Study

    Gad, K. T., Johansen, Christoffer, Duun-Henriksen, A. K., Krøyer, A., Olsen, M. H., Lassen, Ulrik Niels, Mau-Sørensen, M. & Dalton, Susanne Oksbjerg, 1 May 2019, In: Journal of Clinical Oncology. 37, 13, p. 1111-1119

    Research output: Contribution to journal › Journal article › Research › peer-review

  4. Published

    Application of cell-free DNA for genomic tumor profiling: a feasibility study

    Ahlborn, L. B., Rohrberg, K. S., Gabrielaite, M., Tuxen, I. V., Yde, C. W., Spanggaard, I., Santoni Rugiu, Eric, Nielsen, Finn Cilius, Lassen, Ulrik Niels, Mau-Sorensen, M. & Østrup, O., Feb 2019, In: OncoTarget. 10, 14, p. 1388-1398

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24

    Mirza, M. R., Bergmann, T. K., Mau-Sørensen, M., Christensen, R. D., Åvall-Lundqvist, E., Birrer, M. J., Jørgensen, M., Roed, H., Malander, S., Nielsen, F., Lassen, Ulrik Niels, Brøsen, K., Bjørge, L. & Mäenpää, J., 2019, In: Cancer Chemotherapy and Pharmacology. 84, 4, p. 791-798 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer

    Cejalvo, J. M., Jacob, W., Fleitas Kanonnikoff, T., Felip, E., Navarro Mendivil, A., Martinez Garcia, M., Taus Garcia, A., Leighl, N., Lassen, Ulrik Niels, Mau-Soerensen, M., Adessi, C., Michielin, F., James, I., Ceppi, M., Hasmann, M., Weisser, M. & Cervantes, A., 2019, In: ESMO Open. 4, 4, 7 p., e000532.

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Actively personalized vaccination trial for newly diagnosed glioblastoma

    Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., thor Straten, P., Martínez-Ricarte, F., Ponsati, B., Okada, H., Lassen, U., Admon, A., Ottensmeier, C. H., Ulges, A., Kreiter, S., von Deimling, A. & 44 others, Skardelly, M., Migliorini, D., Kroep, J. R., Idorn, M., Rodon, J., Piró, J., Poulsen, H. S., Shraibman, B., McCann, K., Mendrzyk, R., Löwer, M., Stieglbauer, M., Britten, C. M., Capper, D., Welters, M. J. P., Sahuquillo, J., Kiesel, K., Derhovanessian, E., Rusch, E., Bunse, L., Song, C., Heesch, S., Wagner, C., Kemmer-Brück, A., Ludwig, J., Castle, J. C., Schoor, O., Tadmor, A. D., Green, E., Fritsche, J., Meyer, M., Pawlowski, N., Dorner, S., Hoffgaard, F., Rössler, B., Maurer, D., Weinschenk, T., Reinhardt, C., Huber, C., Rammensee, H. G., Singh-Jasuja, H., Sahin, U., Dietrich, P. Y. & Wick, W., 2019, In: Nature. 565, 7738, p. 240-245 6 p.

    Research output: Contribution to journal › Letter › Research › peer-review

  8. Published

    Angiotensinogen promoter methylation to predict bevacizumab response in recurrent glioblastoma patients

    Urup, T., Gillberg, Linn, Kaastrup, K., Lu, M. S., Michaelsen, Signe Regner, Larsen, V. A., Christensen, I. J., Broholm, H., Lassen, Ulrik Niels, Grønbæk, Kirsten & Poulsen, H. S., 2019, In: Neuro-Oncology. 21, Supplement 6, p. vi149

    Research output: Contribution to journal › Conference abstract in journal › Research › peer-review

  9. Published

    Capture and Detection of Circulating Glioma Cells Using the Recombinant VAR2CSA Malaria Protein

    Bang-Christensen, S. R., Pedersen, R. S., Pereira, M. A., Clausen, T. M., Løppke, C., Sand, N. T., Ahrens, T. D., Jørgensen, A. M., Lim, Y. C., Goksøyr, L., Choudhary, S., Gustavsson, T., Dagil, R., Daugaard, M., Sander, A. F., Torp, M. H., Søgaard, M., Theander, T. G., Østrup, O., Lassen, U. & 3 others, Hamerlik, P., Salanti, Ali & Agerbæk, Mette Ørskov, 2019, In: Cells. 8, 9, 21 p., 998.

    Research output: Contribution to journal › Journal article › Research › peer-review

  10. Published

    Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Nørøxe, D. S., Østrup, O., Yde, C. W., Ahlborn, L. B., Nielsen, Finn Cilius, Michaelsen, Signe Regner, Larsen, V. A., Skjøth-Rasmussen, J., Brennum, J., Hamerlik, P., Poulsen, H. S. & Lassen, Ulrik Niels, 2019, In: OncoTarget. 10, 43, p. 4397-4406 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    Combining PARP inhibition with PD-1 inhibitors

    Lassen, Ulrik Niels, 2019, In: The Lancet Oncology. 20, 9, p. 1196-1198 3 p.

    Research output: Contribution to journal › Comment/debate › Research › peer-review

  12. Published

    Copenhagen prospective personalized oncology (COPPO)—Clinical utility of using molecular profiling to select patients to phase I trials

    Tuxen, I. V., Rohrberg, K. S., Oestrup, O., Ahlborn, L. B., Schmidt, A. Y., Spanggaard, I., Hasselby, Jane Preuss, Santoni Rugiu, Eric, Yde, C. W., Mau-Sørensen, M., Nielsen, Finn Cilius & Lassen, Ulrik Niels, 2019, In: Clinical Cancer Research. 25, 4, p. 1239-1247 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  13. Published

    Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations

    Dombernowsky, T., Hædersdal, Merete, Lassen, Ulrik Niels & Thomsen, Simon Francis, 2019, In: Trials. 20, 12 p., 708.

    Research output: Contribution to journal › Journal article › Research › peer-review

  14. Published

    Extracranial metastases in glioblastoma—Two case stories

    Schou Nørøxe, D., Michaelsen, Signe Regner, Broholm, H., Møller, Søren, Skovgaard Poulsen, H. & Lassen, Ulrik Niels, 2019, In: Clinical Case Reports. 7, 2, p. 289-294 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  15. Published

    High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

    Bertelsen, B., Tuxen, I. V., Yde, C. W., Gabrielaite, M., Torp, M. H., Kinalis, S., Oestrup, O., Rohrberg, K., Spangaard, I., Santoni Rugiu, Eric, Wadt, Karin Anna Wallentin, Mau-Sorensen, M., Lassen, Ulrik Niels & Nielsen, Finn Cilius, 2019, In: npj Genomic Medicine. 4, 1, 11 p., 13.

    Research output: Contribution to journal › Journal article › Research › peer-review

  16. Published

    How I treat NTRK gene fusion-positive cancers

    Lassen, Ulrik Niels, 2019, In: ESMO Open. 4, Suppl. 2, 3 p., e000612.

    Research output: Contribution to journal › Review › Research › peer-review

  17. Published

    Identification of Tumor Antigens Among the HLA Peptidomes of Glioblastoma Tumors and Plasma

    Shraibman, B., Barnea, E., Kadosh, D. M., Haimovich, Y., Slobodin, G., Rosner, I., López-Larrea, C., Hilf, N., Kuttruff, S., Song, C., Britten, C., Castle, J., Kreiter, S., Frenzel, K., Tatagiba, M., Tabatabai, G., Dietrich, P-Y., Dutoit, V., Wick, W., Platten, M. & 17 others, Winkler, F., von Deimling, A., Kroep, J., Sahuquillo, J., Martinez-Ricarte, F., Rodon, J., Lassen, Ulrik Niels, Ottensmeier, C., van der Burg, S. H., Thor Straten, P., Poulsen, H. S., Ponsati, B., Okada, H., Rammensee, H., Sahin, U., Singh, H. & Admon, A., 2019, In: Molecular and Cellular Proteomics. 18, 6, p. 1255-1268 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  18. Published

    Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

    Viller Tuxen, I., Barlebo Ahlborn, L., Mau-Soerensen, M., Staal Rohrberg, K., Nielsen, Finn Cilius, Oestrup, O., Westmose Yde, C., Richter Vogelius, I. & Lassen, Ulrik Niels, 2019, In: British Journal of Cancer. 121, 2, p. 125-130 6 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  19. Published

    Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial

    de Bono, J. S., Concin, N., Hong, D. S., Thistlethwaite, F. C., Machiels, J. P., Arkenau, H. T., Plummer, R., Jones, R. H., Nielsen, D., Windfeld, K., Ghatta, S., Slomovitz, B. M., Spicer, J. F., Yachnin, J., Ang, J. E., Mau-Sørensen, P. M., Forster, M. D., Collins, D., Dean, E., Rangwala, R. A. & 1 others, Lassen, Ulrik Niels, 2019, In: The Lancet Oncology. 20, 3, p. 383-393 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

ID: 4952653